Trial Profile
Thymidylate synthase (TS) polymorphisms (Pol) in genomic DNA as a clinical outcome predictor in patients (pts) with advanced non-small cell lung cancer (NSCLC) receiving pemetrexed (Pem)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Dec 2015 New trial record